1. By measuring the binding of N-[3H-methyl]-scopolamine ([3H]-NMS) and of unlabelled subtype-specific muscarinic antagonists, two populations of muscarinic binding sites can be distinguished in the membranes of cardiac ventricles taken from 1-day-old chicks. One of them, corresponding to approximately 80% of [3H]-NMS binding sites, has higher affinities for AF-DX116 (pKi = 6.42) and methoctramine (pKi = 7.33); the rate of [3H]NMS dissociation from these sites is fast. The other population, corresponding to approximately 20% of [3H]-NMS binding sites, has lower affinities for AF-DX116 (pKi = 5.00) and methoctramine (pKi = 6.19); the rate of [3H]-NMS dissociation from these sites is slow. Both populations have high affinities for pirenzepine, but the affinity of the former (major) population is lower (pKi = 7.99) than that of the latter (minor) population (pKi = 10.14). 2. Since it has been shown earlier that two mRNAs for muscarinic receptors are expressed in the chick heart, one of them close to the genetically defined m2 and the other to the m4 subtype, we propose that the major population of binding sites with high affinities for AF-DX116 and methoctramine and the lower affinity for pirenzepine represents the M2-like receptors, while the minor population represents the M4-like receptors. 3. It proved possible to obtain isolated samples of either population by selectively protecting the M2-like sites with AF-DX116 and the M4-like sites with pirenzepine, and by inactivating the unprotected sites with benzilylcholine mustard. The properties of the isolated populations corresponded to those derived from the analysis of [3H]-NMS binding to the original mixed population.4 Alcuronium exerted positive allosteric action on the binding of [3H]-NMS both to the M2-like and the M4-like population and severely slowed down [3H]-NMS dissociation from them; its affinity for the M2-like sites was 3-10 times higher.

Institute of Physiology Academy of Sciences of the Czech Republic Prague

See more in PubMed

Mol Pharmacol. 1985 May;27(5):525-31 PubMed

Mol Pharmacol. 1983 May;23(3):551-7 PubMed

J Pharmacol Exp Ther. 1986 Jan;236(1):219-23 PubMed

J Pharmacol Exp Ther. 1986 Mar;236(3):602-9 PubMed

Eur J Pharmacol. 1987 Jul 23;139(3):359-60 PubMed

Mol Pharmacol. 1988 Feb;33(2):187-94 PubMed

Br J Pharmacol. 1988 Feb;93(2):357-66 PubMed

Pharmacol Ther. 1988;37(3):357-423 PubMed

J Pharmacol Exp Ther. 1988 Nov;247(2):596-602 PubMed

J Auton Pharmacol. 1988 Sep;8(3):259-66 PubMed

Mol Pharmacol. 1989 Apr;35(4):469-76 PubMed

Trends Neurosci. 1989 Apr;12(4):148-51 PubMed

Mol Pharmacol. 1989 May;35(5):553-8 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 1989 Sep;340(3):279-84 PubMed

J Biol Chem. 1990 Feb 15;265(5):2828-34 PubMed

Annu Rev Pharmacol Toxicol. 1990;30:633-73 PubMed

Mol Pharmacol. 1990 Aug;38(2):267-73 PubMed

Mol Pharmacol. 1990 Nov;38(5):674-80 PubMed

Mol Pharmacol. 1990 Dec;38(6):805-15 PubMed

J Pharmacol Exp Ther. 1991 Feb;256(2):468-79 PubMed

Br J Pharmacol. 1991 Jan;102(1):246-50 PubMed

Biochem Pharmacol. 1991 Jul 5;42(2):199-205 PubMed

J Biol Chem. 1991 Sep 15;266(26):17382-7 PubMed

Biochem Pharmacol. 1991 Oct 24;42(10):1927-32 PubMed

Pharmacol Ther. 1993 Jun;58(3):319-79 PubMed

Mol Pharmacol. 1994 Apr;45(4):709-17 PubMed

Eur J Pharmacol. 1994 Mar 3;253(3):275-81 PubMed

Mol Pharmacol. 1966 Jul;2(4):284-97 PubMed

Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 PubMed

Br J Pharmacol. 1976 Nov;58(3):323-31 PubMed

Anal Biochem. 1977 Dec;83(2):346-56 PubMed

Anal Biochem. 1980 Sep 1;107(1):220-39 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 1985 Apr;329(2):176-81 PubMed

Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists

Subtype-selective inhibition of [methyl-3H]-N-methylscopolamine binding to muscarinic receptors by alpha-truxillic acid esters